PR83915

SEOUL, Korea, May 19, 2020 /PRNewswire=KYODO JBN/--

Seegene to secure a bridgehead for leading MDx market in Latin America

Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies

headquartered in South Korea, announced that it will export 10 million tests of

its COVID-19 testing kits to Pan American Health Organization (PAHO) / World

Health Organization (WHO) through Brazilian subsidiary, Seegene do Brasil

Diagnosticos Ltda.

Seegene has supplied 5 million tests of Allplex(TM) 2019-nCOV assay to Brazil

and will supply remaining tests in the following weeks. Also, Seegene will

discuss a further increase of up to 100% of the testing volume.

The company said, "This unprecedentedly large export volume emphasizes an

explosive increase in demand for Seegene's COVID-19 product worldwide and

demonstrates that our high volume testing system is gaining world recognition."

Seegene's Allplex(TM) 2019-nCOV Assay is eyeing a good response from the market

as the capability of the assay that identifies 3 different target genes (E

gene, RdRP gene and N gene) in a single-tube enables accurate and efficient

diagnosis, and Seegene's automated system is extremely useful during the

coronavirus pandemic where large volume of tests are required.

Seegene has already exported 20 million tests of the COVID-19 assays to over 60

countries and is ramping up the production rapidly to meet an increased demand

across the globe.

The export volume to the Brazilian market is expected to rise as Seegene is

negotiating supply agreement with the state government and private laboratories

in Brazil. In addition, the company is planning with PAHO for further contracts

with other countries in Latin America.

As Seegene's assay is already well-recognized in major European countries such

as France, Germany, Italy and Spain, the company's solution for COVID-19

diagnosis surely secures a bridgehead for expanding the market presence to

Latin America. This contract indeed marks a significant beginning for Seegene

to further occupy the molecular diagnostics market in all of the countries in

Latin America.  

About Seegene

Seegene (KQ : 096530) is a global pioneer in symptom-based in vitro molecular

diagnostics focusing on advancing science to develop multiplex molecular

technologies and to manufacture multiplex in vitro diagnostic devices and

reagents. Seegene's core enabling power is the passion for wide spreading of

multiplex molecular diagnostics to improve the quality of life and health of

people. Using its innovative proprietary technologies, Seegene has been making

considerable contributions to giving the most economic and clinic-friendly

molecular diagnostic solutions for infectious diseases, genetics,

pharmacogenetics, and oncology. For more information, please visit

www.seegene.com.

Joon Kim

kjh8363@seegene.com

Jisoo Lee

jislee@seegene.com

SOURCE: Seegene